Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer

GAO Tianming; FU Qiang; CONG Lili; CUI Chenli; LIU Qing

PDF(733 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2020, Vol. 31 ›› Issue (4) : 313-316.

Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer

GAO Tianming¹, FU Qiang¹, CONG Lili¹, CUI Chenli¹, LIU Qing²

Author information +

History +

Abstract

Objective To investigate the clinical efficacy of medroxyprogesterone acetate combined with tamoxifen in the treatment of endometrial cancer and its effect on serum levels of TSGF, PRL and HE4.Methods 105 patients with endometrial cancer admitted to the hospital from March 2016 to December 2018 were randomly divided into 2 groups. 50 cases in the control group were treated with medroxyprogesterone acetate tablets, 55 cases in the observation group were treated with medroxyprogesterone acetate tablets combined with tamoxifen citrate tablets. After 12 weeks of treatment, the recent treatment effect and adverse reactions of the two groups were observed, and the expression levels of TSGF, PRL and HE4 in the serum of the two groups before and after treatment were detected by enzyme-linked immunosorbent assay (ELISA).Results After 12 weeks of treatment, the effective rate of the control group was 42.00%, the clinical benefit rate was 68.00%; the effective rate of the observation group was 65.45%, the clinical benefit rate was 85.45%; the difference of the effective rate and the clinical benefit rate between the two groups was statistically significant (P The results showed that the expression of TSGF, PRL and HE4 in the serum of the patients in the observation group was significantly lower than that in the control group (P<0.05); the incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05).Conclusions Medroxyprogesterone acetate combined with tamoxifen can improve the clinical therapeutic effect of endometrial cancer and reduce the expression level of serum TSGF, PRL and HE4. Its clinical effect may be related to the expression of serum TSGF, PRL and HE4.

Key words

endometrial cancer / medroxyprogesterone acetate / tamoxifen / human epididymis secreted protein

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

GAO Tianming, FU Qiang, CONG Lili, CUI Chenli, LIU Qing. Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(4): 313-316

References

[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA: A Cancer J Clin, 2011, 61(2): 69-90.
[2] 杨曦, 马珂, 吴成. 子宫内膜癌的流行病学及高危因素[J]. 实用妇产科杂志, 2015, 31(7): 485-488.
[3] Adamiak-Godlewska A, Tarkowski R, Winkler I, et al. Stress urinary incontinent women, the influence of age and hormonal status on estrogen receptor alpha and beta gene expression and protein immunoexpression in paraurethral tissues[J]. J Physiol Pharmacol, 2018, 69(1):53-59.
[4] 张凯, 郭飞, 王颖梅, 等. 新辅助化疗在中晚期子宫内膜癌治疗中的研究进展[J]. 中国妇产科临床杂志, 2018, 19(1): 87-89.
[5] 张一琼, 于江燕, 朱元方. 子宫内膜癌肿瘤微环境的研究进展[J]. 现代肿瘤医学, 2016, 24(16):2651-2655.
[6] 王志启. 醋酸甲地孕酮和他莫昔芬治疗晚期子宫内膜癌的Ⅱ期试验－GOG的一项研究[J]. 国际妇产科学杂志, 2004, 31(6): 390-391.
[7] 符晶莹. 复方苦参注射液联合醋酸甲地孕酮治疗子宫内膜癌的疗效观察[J]. 现代药物与临床, 2016, 31(6): 855-858.
[8] 周际昌, 谢惠民. 新编抗肿瘤药物临床治疗手册[M]. 北京: 中国协和医科大学出版社, 2004: 237-386.
[9] Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol, 2004, 22(1): 19-22.
[10] 步华磊, 靳成娟, 王霞, 等. 子宫内膜癌卵巢转移高危因素的Meta分析[J]. 现代妇产科进展, 2017, 26(4): 287-292.
[11] 李海萍. HIF-1α、CXCR4及VEGF在子宫内膜癌组织中的表达及意义[J]. 中国老年学杂志, 2017, 37(15): 3782-3784.
[12] 虞斌, 许培箴, 王秋伟,等. 肿瘤特异性生长因子在子宫内膜癌的应用价值[J]. 中国现代医学杂志, 2005, 15(14): 2199-2201.
[13] 邵志翔, 王晓芳. CEA、TSGF以及CA19-9联合检测在胃癌诊疗中的临床价值[J]. 中国实验诊断学, 2017, 21(2): 228-231.
[14] 宋秀军, 刘建红, 吕进. PRL-3在肿瘤中作用机制的研究进展[J]. 临床肿瘤学杂志, 2017, 22(6):566-569.
[15] 陈欢欢, 王新会, 李盛, 等. TC方案化疗联合手术对子宫内膜癌患者血清TSGF、PRL、HE4及炎性因子水平的影响[J]. 海南医学院学报, 2017, 23(5): 705-708, 712.
[16] 王英, 李佩章, 黄玲莎, 等. HE4和CA153联合表达在预测早期乳腺癌淋巴结转移中的意义[J]. 现代肿瘤医学, 2017, 25(3): 63-65.
[17] Angioli R, Plotti F, Capriglione S, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study[J]. Tumour Biol, 2013, 34(1): 571-576.
[18] 马瑞兰, 李国权, 徐晓颖,等. 血浆催乳素水平与绝经前乳腺癌危险性的关系评估[J]. 蚌埠医学院学报, 2015, 40(1):64-66.